Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) dropped 2.2% during mid-day trading on Thursday . The company traded as low as $0.13 and last traded at $0.14. Approximately 8,794,663 shares changed hands during trading, a decline of 48% from the average daily volume of 16,965,762 shares. The stock had previously closed at $0.14.
Wall Street Analysts Forecast Growth
Separately, Noble Financial raised shares of Zomedica to a “strong-buy” rating in a research report on Monday, November 11th.
Get Our Latest Analysis on Zomedica
Zomedica Stock Performance
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Zomedica stock. Jane Street Group LLC bought a new position in Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 179,074 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 8.95% of the company’s stock.
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Featured Articles
- Five stocks we like better than Zomedica
- What Are Dividend Challengers?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- How to Read Stock Charts for Beginners
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Are the FAANG Stocks and Are They Good Investments?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.